DBV Technologies (DBVT) Other Non-Current Assets (2015 - 2026)
DBV Technologies (DBVT) reported Other Non-Current Assets of $5.4 million for Q1 2026, up 8.87% year-over-year from $5.0 million in Q1 2025, and down 6.9% quarter-over-quarter from $5.8 million in Q4 2025.
DBV Technologies (DBVT) Other Non-Current Assets (2015 - 2026) Analysis & Trends
DBV Technologies (DBVT) has 12 years of Other Non-Current Assets data on file, last reported at $5.4 million in Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $5.4 million, up 8.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.4 million (up 8.87% YoY), and the FY2025 annual result was $5.8 million, up 31.13% from the prior year.
- Other Non-Current Assets declined to $5.4 million in Q1 2026 per DBVT's latest filing, from $5.8 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $6.8 million in Q1 2024 and troughed at $4.4 million in Q4 2024.
- A 5-year average of $5.7 million and a median of $5.8 million in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets slumped 84.03% in 2022, then surged 31.13% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $5.8 million in 2022, then advanced by 5.49% to $6.1 million in 2023, then fell by 28.01% to $4.4 million in 2024, then surged by 31.13% to $5.8 million in 2025, then dropped by 6.9% to $5.4 million in 2026.
- Business Quant data shows DBVT's Other Non-Current Assets at $5.4 million in Q1 2026, $5.8 million in Q4 2025, and $5.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | DBV Technologies | 6.63 Bn | 6.41 Bn | -3.90 Mn | 5.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.40 Mn |
| Dec 31, 2025 | 5.80 Mn |
| Sep 30, 2025 | 5.46 Mn |
| Jun 30, 2025 | 5.33 Mn |
| Mar 31, 2025 | 4.96 Mn |
| Dec 31, 2024 | 4.42 Mn |
| Sep 30, 2024 | 5.28 Mn |
| Jun 30, 2024 | 5.35 Mn |
| Mar 31, 2024 | 6.82 Mn |
| Dec 31, 2023 | 6.14 Mn |
| Sep 30, 2023 | 5.97 Mn |
| Jun 30, 2023 | 5.94 Mn |
| Mar 31, 2023 | 5.77 Mn |
| Dec 31, 2022 | 5.82 Mn |
| Sep 30, 2022 | 5.37 Mn |
| Jun 30, 2022 | 6.19 Mn |
| Mar 31, 2022 | 6.58 Mn |
| Dec 31, 2021 | 6.83 Mn |
| Sep 30, 2021 | 33.61 Mn |
| Jun 30, 2021 | 32.76 Mn |